Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2009

Healthcare costs for new technologies

Authors: Mathias Goyen, Jörg F. Debatin

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2009

Abstract

Introduction

Continuous ageing of the population coupled with growing health consciousness and continuous technological advances have fueled the rapid rise in healthcare costs in the United States and Europe for the past several decades. The exact impact of new medical technology on long-term spending growth remains the subject of controversy. By all measures it is apparent that new medical technology is the dominant driver of increases in health-care costs and hence insurance premiums.

Objective

This paper addresses the impact of medical technology on healthcare delivery systems with regard to medical practice and costs. We first explore factors affecting the growth of medical technology and then attempt to provide a means for assessing the effectiveness of medical technology.

Discussion

Avoidable healthcare cost drivers are identified and related policy issues are discussed.

Centers for Medicare and Medicaid Services. National health expenditure data. Baltimore, MD: Centers for Medicare and Medicaid Services; 2008. http://www.cms.hhs.gov/NationalHealthExpendData/.

Nichols LM. Can defined contribution health insurance reduce cost growth? EBRI issue brief, no. 246. Washington DC: Employee Benefit Research Institute; 2002.

AdvaMed. The value of investment in health care: better care, better lives. Washington DC: Advanced Medical Technology Association; 2004. http://www.advamed.org/NR/rdonlyres/10CB7E4D-FBF4-4874-9CF7-3A85D2A0EF6B/0/medtapreport.pdf.

Rettig RA. Medical innovation duels cost containment. Health Affairs 1994:15 (summer).

Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000;10:1441–56.CrossRef

Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000;11:1598–609.CrossRef

Anderson GF, Frogner BK, Johns RA, Reinhardt UE. Health care spending and use of information technology in OECD countries. Health Affairs 2006;25:819–31.PubMedCrossRef

Newhouse JP. Medical care costs: how much welfare loss? J Econ Perspect 1992;6:3–21.PubMed

Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960–2000. N Engl J Med 2006;355:920–7.PubMedCrossRef

Title: Healthcare costs for new technologies
Authors: Mathias Goyen
Jörg F. Debatin
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0975-y

At a glance: The STEP trials

Springer Medicine

Healthcare costs for new technologies

Abstract

Introduction

Objective

Discussion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Objective

Discussion

Please log in to get access to this content

Other articles of this Special Issue 1/2009

PET/MRI: a different spin from under the rim

PET/MRI system design

A decade of combined imaging: from a PET attached to a CT to a PET inside an MR

A look ahead: PET/MR versus PET/CT

Risks and safety aspects related to PET/MR examinations

Magnetic resonance imaging methodology